Trial Profile
A retrospective study analysing the switch to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in asymptomatic HIV infected patients on HAART
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2016
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2016 New trial record
- 15 Feb 2016 Results published in the European Journal of Clinical Microbiology and Infectious Diseases